Updates in Best Practices in Non-Small Cell Lung Cancer

Slides:

Advertisements

Similar presentations

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Advertisements

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Metastatic HER2+ Breast Cancer: Resistance

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Patient Case 1 Patient Case 1: PET/CT Scan.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Unità Clinica di Diagnostica Istopatologica e Molecolare

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Treatment Algorithms in Melanoma: Past, Present, and Future

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

Spotlight on Immuno-Oncology in Melanoma

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Basics of Immunotherapy Potential Therapeutic Targets.

Treating mRCC After Initial Antiangiogenic Therapy:

Immunotherapy for cSCC

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Immune Checkpoint Inhibitors in Lung Cancer

University of British Columbia British Columbia Cancer Agency

Locally Advanced Lung Cancer

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Critical Decision Points in Insomnia

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Optimizing Characterization of NSCLC Through Specialty Collaboration

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Third-Generation EGFR TKIs

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Physiologic vs Chronologic Age

Evaluating the Totality of Evidence

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

Physiologic vs Chronologic Age

Uncovering the Right Sequence

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Updates in Best Practices in Non-Small Cell Lung Cancer

Program Overview

Treatment Schema for Patients with NSCLC

Molecular Testing Is Key

EGFR-Targeted Agents With Features of the TKIs

How to Select Between EGFR TKIs

ARCHER 1050 Study: Dacomitinib vs Gefitinib in EGFR Mutation-Positive Lung Cancer

Dacomitinib Dose Adjustment Does Not Affect PFS

Sequencing Therapy

NSCLC Evolves Over Time

AURA 3 Trial: Assessing Acquired Resistance Mutations

Osimertinib is Active in Patients With Brain Metastases

Multidisciplinary Management Important for Treatment of NSCLC With Brain Metastases

Is Cure Possible?

Resistance in EGFR-Positive NSCLC

How to Deal With Resistance

ASPIRATION study

EGFR TKI in Combination with Anti-Angiogenic Agents

Gefitinib + Chemotherapy Shows a Survival Benefit

ALK Inhibitors Summary

Front-Line Selection of ALK TKI

Resistance to ALK TKI

The Future for EGFR and ALK TKI

Immunotherapy an Option After Progression?

Concluding Remarks

Abbreviations